Savara (SVRA) Share-based Compensation (2010 - 2026)
Savara (SVRA) reported Share-based Compensation of $10.7 million for Q1 2026, up 260.94% year-over-year from $3.0 million in Q1 2025, and up 100.32% quarter-over-quarter from $5.4 million in Q4 2025.
Savara (SVRA) Share-based Compensation (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Share-based Compensation data on file, last reported at $10.7 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $10.7 million, up 260.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.2 million (up 109.7% YoY), and the FY2025 annual result was $14.4 million, up 46.26% from the prior year.
- Share-based Compensation climbed to $10.7 million in Q1 2026 per SVRA's latest filing, from $5.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.7 million in Q1 2026 and troughed at $450000.0 in Q3 2022.
- A 5-year average of $2.4 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation tumbled 40.86% in 2022, then surged 260.94% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $561000.0 in 2022, then jumped by 142.6% to $1.4 million in 2023, then surged by 123.07% to $3.0 million in 2024, then jumped by 76.38% to $5.4 million in 2025, then jumped by 100.32% to $10.7 million in 2026.
- Business Quant data shows SVRA's Share-based Compensation at $10.7 million in Q1 2026, $5.4 million in Q4 2025, and $3.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 26.47 Mn |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | 10.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.73 Mn |
| Mar 31, 2026 | 10.73 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Dec 31, 2023 | 1.36 Mn |